Replay develops gene therapies designed to deliver large genetic payloads, with a focus on rare inherited skin diseases. Its engineered herpes simplex virus platform builds on technology developed by Joseph Glorioso’s team at the University of Pittsburgh and licensed to Replay. The platform supports topical delivery and the potential for repeat treatment. [1] [2]
Cofounded by Adrian Woolfson, Lachlan MacKinnon, David Knipe and Ron Weiss, Replay launched with $55 million in seed financing in 2022. In April 2026, LEO Pharma announced an agreement to acquire the company and advance its dermatology platform, including a preclinical program for dystrophic epidermolysis bullosa, a disease that causes fragile, blistering skin. [3] [2]